
Welcome to the arena. This is Galen, Chief Physician of the Gladiators. I’m here to equip you for greatness. Because the sharpest warriors are always up-to-date on the latest advancements in health and longevity. Nobody’s dying anytime soon on my watch.
Today’s Roundup:
1. Whoop partners with Abu Dhabi on health research
Abu Dhabi’s Department of Health signed a 24-month research partnership with Whoop on October 21st. This partnership follows a $75M investment from Abu Dhabi’s state fund in Whoop’s $10.1B funding round this past May. Whoop also notes its membership in the Gulf region (UAE, Saudi Arabia, Qatar + neighbors) grew 75+% in the past year.
Their 1st study will run for 6 months in adults with obesity and high blood pressure. Tracked biometrics will include weight, blood pressure, cholesterol, blood sugar, and sleep.
Abu Dhabi steps in after $75M investment to help test Whoop’s wearable-plus-coaching model for preventing heart and metabolic disease.
released: Wed, 10/21/2026
source: Emirates News Agency report
2. GLP-1s beat metformin at preventing diabetes, heart problems & death in prediabetics
Mayo Clinic researchers compared 256,492 adults with prediabetes and obesity, half on a GLP-1 drug and half on metformin*, over ~3 years. GLP-1s came out on top…
Likelihood of getting blood sugar back to normal: 1.5x more likely GLP-1👑 vs. metformin
Risk of developing diabetes: 31% lower GLP-1👑 vs. metformin
Risk of death: 41% lower GLP-1👑 vs. metformin
Instances of heart attacks, strokes, and heart failure cases: 15-25% fewer GLP-1👑 vs. metformin
GLP-1 dethrones metformin as the “superior prediabetic treatment option,” given its greater blood sugar regulation capabilities and decreased risks of escalation into diabetes, death, or cardiovascular emergencies.
*Metformin—for those who aren’t familiar—is a cheap generic pill that’s been the standard diabetes treatment for decades; it lowers blood sugar mainly by reducing how much sugar the liver releases and has a long safety record.
released: Mon, 11/02/2026
source: American Heart Association press release
3. The peptide rush is here—with or without FDA approval
The US Department of Health and Human Services (HHS) says it will now let licensed pharmacies make 6 popular peptides with a doctor’s prescription.
None of the 6 peptides are FDA-approved, and most of the evidence for them comes from animal studies. The government simply chose to stop cracking down on pharmacies that make them, overruling its own FDA staff’s advice.
Telehealth companies didn't waste a second: within days, sites were selling them for about $199–$249 a month. Hims & Hers opened a waitlist for its own peptide line, and its stock jumped 5% the day the news hit, with analysts estimating the peptide market could reach as much as $3.3 billion.
The 6 Peptides:
BPC-157: used for healing injuries and the gut. People take it to speed recovery of tendons, ligaments and muscles, and for gut issues like ulcers and leaky gut.
Origins: fragment of a protein found in stomach juiceTB-500: used for tissue repair and recovery. Popular with athletes and is often stacked with BPC-157 for injuries.
Origins: lab-made piece of thymosin beta-4, protein involved in wound healing and growth of new blood vesselsEpitalon: promoted for anti-aging.
Origins: lab-made peptide that’s claimed to switch on telomerase, the enzyme that protects the ends of chromosomes, and to support melatonin and sleepKPV: used against inflammation, especially in the gut and skin.
Origins: tiny fragment of a natural anti-inflammatory hormoneMOTS-c: used for metabolism and exercise capacity.
Origins: made by the mitochondria and is studied for insulin sensitivity, fat burning and enduranceSemax: used for focus, memory, and brain recovery. Biohackers use it as a nootropic, a focus-and-memory booster.
Origins: nasal spray developed in Russia, where it’s approved for stroke and some cognitive conditions
released: Wed, 10/28/2026
source: TIME news article
4. Ultra-processed food linked to belly fat and silent brain blood-vessel damage
In a study of 8,783 Canadian adults aged 35-69, ultra-processed food (UPF) intake was compared with MRI scans and thinking tests. The following conclusions were drawn:
- The top 25% of UPF consumers had more visceral (belly) fat*
- The top 25% of UPF consumers had 40% higher odds of silent blood-vessel damage in the brain
- No significant difference seen in thinking-test scores.
Increased UPF consumption is bad for brain health and contributes to increased visceral fat which is bad for longevity/overall health.
*A note on visceral fat: tied to a higher risk of early death, even in those who are not overweight; releases inflammatory chemicals and fatty acids into the liver which drives insulin resistance, heart disease, T2 diabetes, and dementia
released: Thu, 10/15/2026
source: Peer-reviewed observational research paper, JAMA Network Open
5. Oura launches GLP-1 trial with UC San Diego
Oura’s 1st clinical trial, SMART-BMI, will follow up to 260 adults who are starting a GLP-1 drug or having weight-loss surgery over 52 weeks.
Everyone wears an Oura Ring 4. In the trial’s 2nd phase, everyone also gets a health coach, but only half of the care teams can access the ring data. The main question is whether the Oura ring data improves weight loss, with A1C, blood pressure, and staying on the medication also tracked.
Oura, a consumer smart ring, undergoes its first testing as a clinical tool in GLP-1 and bariatric-surgery care.
released: Wed, 10/28/2026
source: Oura press release
Take complete agency over your health and longevity
